NCT06850506

Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment

Active, enrolled Last updated 27 February 2025

What this trial tests

trial in Sarcoma in 70 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 September 2024

Primary endpoint
1 September 2025

1 September 2025

Quick facts

Lead sponsor	Peking University People's Hospital
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	70
Start date	1 September 2024
Primary completion	1 September 2025
Estimated completion	1 September 2025
Sites	1 location across China

Conditions studied

• Sarcoma — all drugs for Sarcoma →
• Sarcoma, Bone — all drugs for Sarcoma, Bone →
• Ewing Sarcoma — all drugs for Ewing Sarcoma →
• Osteosarcoma — all drugs for Osteosarcoma →

Sponsor

Peking University People's Hospital

Who can join

Adults 12 to 70, any sex, with Sarcoma or Sarcoma, Bone. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Evaluate the feasibility of using immunohistochemistry to detect the expression level of CDH6 in histological white slides of patients with osteosarcoma and Ewing's sarcoma as a biological marker for prognostic monitoring The patient's initial visit was clinically diagnosed as high-grade osteosarcoma or Ewing's sarcoma. The informed consent form for specimen monitoring was signed first. During the puncture biopsy, fresh tissue (soft tissue component, not bone tissue) with a volume of about 1cm3 was taken, fixed with formalin solution, and tissue slices (white slices) with a thickness of 5 microns were cut, smeared, and baked. Immunohistochemistry staining was used for CDH6 expression analysis (XP) ® Cadherin-6 (D3T3I) Rabbit mAb Cat:#48111, CellSignaling Technology）。
2. Treatment process and follow-up The routine neoadjuvant chemotherapy regimen for osteosarcoma in our center includes sequential use of cisplatin, high-dose doxorubicin, methotrexate, and ifosfamide, while the VDC-IE regimen is used for Ewing sarcoma (see Figure 3.1.1A, B for details). Due to the significant heterogeneity of osteosarcoma cells, the subpopulations of cells affected by each drug are not the same, and there are also differences in the subpopulations of necrotic and lysed cells after medication. The expression level of CDH6 in patient tissue slices will dynamically change with the sensitivity of chemotherapy. While conducting clinical evaluations, if given the opportunity, we will try to compare the changes in CDH6 levels in tissue sections to assess their value for efficacy monitoring.

Patients usually undergo surgical treatment after neoadjuvant chemotherapy, and the tumor burden decreases sharply after surgery. The gross tumor specimen obtained during surgery should be retained with qualified tumor tissue samples (at least 1cm3 in volume). During the tumor treatment process, if there is an opportunity for surgery, biopsy or resection of tumor tissue should be performed again to monitor changes in CDH6 expression levels. Clinical evaluation of tumor treatment should be conducted every two months until the end of the study or patient death.

The entire study includes a screening period, blood collection and specimen retention period, and follow-up period. All participants in the study must meet all inclusion and exclusion criteria.

During the screening period, potential participants will undergo eligibility assessment for the study after signing the informed consent form. Subjects must undergo radiographic evaluation of the disease within 14 days prior to neoadjuvant chemotherapy, including enhanced CT or MRI of the primary tumor site, chest plain scan CT, ECT whole-body bone imaging, or whole-body PET/CT.

The subjects will receive chemotherapy and surgical treatment according to the diagnosis and treatment routine, and at the time nodes designed in the experiment, before and after the subjects' routine chemotherapy and surgery, the pathology department will take 3 white slides, each measuring 4 microns, smear and bake gel, and perform immunohistochemical staining.

During the follow-up period, the subjects have completed chemotherapy and surgical treatment, but will still receive follow-up on their survival status and oncology status, and all follow-up will be routine treatment at our center.
3. We will use FFPE tumor tissue samples for immunohistochemical staining to analyze the expression of CDH6, β - catenin, and CDH17 in tumor tissue.

Immunohistochemical staining:

Primary antibody: CDH6 rabbit monoclonal antibody (D3T3I); β - catenin rabbit monoclonal antibody (D10A8); CDH17 mouse monoclonal antibody (Xianxiang internal antibody); Secondary antibody detection system: Bond Polymer Refine Detection Kit； Antibody diluent: CST,8112L,#38； Positive photos: FFPE sections of low, medium, and high expression cell lines; The staining program uses the established method of Xianxiang.

Pathological interpretation:

Use H-score for semi quantitative analysis. H-score is the sum of the percentage of cell staining multiplied by the corresponding intensity values (0=negative, 1=1+, 2=2+, 3=3+), ranging from 0 to 300.

The interpretation of tumor cell staining intensity values is as follows:

High expression (3+): Strong cell membrane staining and/or cytoplasmic staining were observed under x4 magnification; Moderate expression (2+): Cell membrane staining was observed at x10 or x20 magnification; Low expression (1+): weak cell membrane staining and/or cytoplasmic staining were observed at x40 magnification; Negative (0): No cell membrane staining and/or cytoplasmic staining was observed in tumor cells.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.